Hequn Zou

Prof. Dr. Hequn Zou

1. Department of Nephrology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen, China
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in The Lancet Global Health
Verified
Journal Article
Open access
Bogdan Ene-IordacheBogdan Ene-Iordache
Bogdan Ene-Iordache
NPNorberto Perico
Norberto Perico
BBBoris Bikbov
Boris Bikbov
SCSergio Carminati
Sergio Carminati
ARAndrea Remuzzi
Andrea Remuzzi
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi
Chronic kidney disease is an important cause of global mortality and morbidity. Data for epidemiological features of chronic kidney disease and its risk factors are limited for low-income and middle-income countries. The International Society of Nephrology's Kidney Disease Data Center (ISN-KDDC) aimed to assess the prevalence and awareness of chronic kidney disease and its risk factors, and to investigate the risk of cardiovascular disease, in countries of low and middle income. We did a cross-sectional study in 12 countries from six world regions: Bangladesh, Bolivia, Bosnia and Herzegovina, China, Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, and Nigeria. We analysed data from screening programmes in these countries, matching eight general and four high-risk population cohorts collected in the ISN-KDDC database. High-risk cohorts were individuals at risk of or with a diagnosis of either chronic kidney disease, hypertension, diabetes, or cardiovascular disease. Participants completed a self-report questionnaire, had their blood pressure measured, and blood and urine samples taken. We defined chronic kidney disease according to modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria; risk of cardiovascular disease development was estimated with the Framingham risk score. 75,058 individuals were included in the study. The prevalence of chronic kidney disease was 14·3% (95% CI 14·0-14·5) in general populations and 36·1% (34·7-37·6) in high-risk populations. Overall awareness of chronic kidney disease was low, with 409 (6%) of 6631 individuals in general populations and 150 (10%) of 1524 participants from high-risk populations aware they had chronic kidney disease. Moreover, in the general population, 5600 (44%) of 12,751 individuals with hypertension did not know they had the disorder, and 973 (31%) of 3130 people with diabetes were unaware they had that disease. The number of participants at high risk of cardiovascular disease, according to the Framingham risk score, was underestimated compared with KDIGO guidelines. For example, all individuals with chronic kidney disease should be considered at high risk of cardiovascular disease, but the Framingham risk score detects only 23% in the general population, and only 38% in high-risk cohorts. Prevalence of chronic kidney disease was high in general and high-risk populations from countries of low and middle income. Moreover, awareness of chronic kidney disease and other non-communicable diseases was low, and a substantial number of individuals who knew they were ill did not receive treatment. Prospective programmes with repeat testing are needed to confirm the diagnosis of chronic kidney disease and its risk factors. Furthermore, in general, health-care workforces in countries of low and middle income need strengthening. International Society of Nephrology.

1 February 2002 in Kidney International
Verified
Journal Article
Closed access
ESErwei Song
Erwei Song
HZHequn Zou
Hequn Zou
YYYousheng Yao
Yousheng Yao
APAmanda Proudfoot
Amanda Proudfoot
BABalazs Antus
Balazs Antus
UHUwe Heemann
Uwe Heemann

1 February 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
TCTong Chen
Tong Chen
HCHaishan Chen
Haishan Chen
HXHua Xiao
Hua Xiao
HTHongjuan Tang
Hongjuan Tang
ZXZhicong Xiang
Zhicong Xiang
HZHequn Zou
Hequn Zou
Background: This study aimed to determine the optimal cutoff values and evaluate the associations of neutrophil to high-density lipoprotein cholesterol ratio (NHR) and lymphocyte to high-density lipoprotein cholesterol ratio (LHR) with metabolic syndrome (MetS), stratified by sex. Methods: A large-scale cross-sectional survey was conducted among 1401 adults from January to April 2018 in six communities in Wanzhai Town, Zhuhai City, on the southern coast of China. Receiver operating characteristics (ROC) analyses and logistic regression analysis were conducted to assess the optimal cutoff and value of NHR and LHR for predicting MetS. Results: Hematological parameters showed the correlation with the occurrence of MetS (red blood cells, hemoglobin, and white blood cells and subtypes). Binomial logistic regression analysis found that LHR (OR: 3.671; 95% CI: 2.385– 5.651; p< 0.001) and NHR (OR: 1.728; 95% CI: 1.353– 2.207; p< 0.001) can predict MetS in females, independent of confounding factors. Although LHR (OR: 1.571; 95% CI: 1.001– 2.468; p=0.05) and NHR (OR: 1.163; 95% CI: 0.909– 1.48; p< 0.01) were independent risk factors for MetS in males after adjustment for age, current smoking, current alcohol use, physical activity, educational attainment, waist circumference, systolic pressure, diastolic pressure and hypersensitive C-reactive protein (hs-CRP), when further adjusted for fasting plasma glucose level, LHR and NHR, both lost their independence. ROC curves showed that LHR had the highest AUC for predicting MetS in females and NHR had the highest AUC in males. The cutoff points of LHR and NHR were 1.36 and 2.31 in females, and 1.96 and 3.38 in males. Conclusion: LHR and NHR may become valuable makers and have strong predictive power for predicting MetS, especially in females.

1 February 2000 in Transplantation
Verified
Journal Article
Closed access
OVOndrej Viklický
Ondrej Viklický
HZHequn Zou
Hequn Zou
VMVeronika Muller
Veronika Muller
JLJiri Lacha
Jiri Lacha
ASAttila Szabó
Attila Szabó
UHUwe Heemann
Uwe Heemann
Background. Chronic rejection remains the most frequent cause of renal graft loss over the long term.However, effective treatment of this process is not yet available. SDZ-RAD (40-O-[2-hydroxyethyl]-rapamycin) is a new, orally active rapamycin derivative with potent immunosuppressive activity. We have examined the effects of SDZ-RAD in a well-established model of chronic renal allograft rejection in rats. Methods. Kidneys of Fisher (F334) rats were orthotopically transplanted into bilaterally nephrectomized Lewis recipients. To suppress an initial episode of acute rejection, rats were briefly treated with low doses of cyclosporine for the first 10 days. Thereafter they received either SDZ-RAD (0.5 mg/kg/day) or vehicle. At 24 weeks, functional evaluations were performed, kidneys were harvested, and histological, immunohistological, and reverse transcription-polymerase chain reaction evaluations were performed. Results. Animals treated with SDZ-RAD developed lower proteinuria and less glomerulosclerosis as compared with controls. Additionally SDZ-RAD reduced the infiltration of macrophages and lymphocytes and the expression of intercellular adhesion molecule-1, laminin, and fibronectin. Furthermore, we observed a reduced expression of growth factor mRNA (transforming growth factor-β and platelet-derived growth factor-AA) in these animals. Conclusion. Our results demonstrated that SDZ-RAD effectively ameliorates chronic renal allograft rejection in rats, probably mediated by suppression of growth factors.

1 October 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
HCHaishan Chen
Haishan Chen
CXChongxiang Xiong
Chongxiang Xiong
XSXiaofei Shao
Xiaofei Shao
JNJing Ning
Jing Ning
PGPeichun Gao
Peichun Gao
HZHequn Zou
Hequn Zou
Purpose: Metabolic syndrome (MetS), which is a global public health problem, is a state of chronic low-grade inflammation. This study looked at the changes in hematological parameters and the predictive value of the lymphocyte to high-density lipoprotein cholesterol (HDL-C) ratio (LHR) as a new index in subjects with and without MetS in coastal cities in southern China. Patients and methods: In this cross-sectional study, there were 852 participants (n = 598 with MetS and n = 254 without MetS). MetS was defined in accordance with the National Cholesterol Education Program, Adult Treatment Panel III (NCEP-ATP III) criteria. Results: MetS was positively correlated with white blood cell count, total lymphocyte count, neutrophil count, red blood cell count, hematocrit, hemoglobin, and high-sensitivity C-reactive protein levels (p<0.05). In addition, there was a positive correlation between LHR and the number of metabolic risk factors for MetS. In a logistic regression analysis, LHR (odds ratio: 4.117; 95% CI: 2.766–6.309; p<0.001) was an independent predictor of MetS. When a receiver operating characteristic (ROC) curve analysis was used to assess the value of LHR for predicting MetS, the area under the curve yielded a cut-off value of 1.657, with a sensitivity of 65% and a specificity of 64% (p<0.0001). Conclusion: In summary, MetS can involve changes in blood parameters, and LHR may be a useful marker of inflammation to assess the presence and severity of MetS.

1 November 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
SSSanjib Kumar Sharma
Sanjib Kumar Sharma
HZHequn Zou
Hequn Zou
ATAriunaa Togtokh
Ariunaa Togtokh
Bogdan Ene-IordacheBogdan Ene-Iordache
Bogdan Ene-Iordache
SCSergio Carminati
Sergio Carminati
MTMarcello Tonelli
Marcello Tonelli